PARP inhibitor + AR pathway inhibitor (prostate)
In prostate cancer, blocking androgen signalling makes cells more dependent on PARP, and PARP inhibition weakens AR signalling in turn.
PROpel (olaparib-abiraterone), TALAPRO-2 (talazoparib-enzalutamide, OS benefit), MAGNITUDE (niraparib-abiraterone). Benefit largest in HRR-mutant, present in some all-comer analyses.
Pages like this
not linked directly; found by shared links- ProductRelugolix
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor signalling, Prostate cancer.
- ProductBicalutamide
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor signalling, Prostate cancer.
- ProductIniparib
Shares Talazoparib, PARP inhibitors, Olaparib.
- ProductApalutamide
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor signalling, Prostate cancer.
- ProductDarolutamide
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor signalling, Prostate cancer.
- IdeactDNA-guided duration of PARP maintenance
Shares Niraparib, PARP inhibitors, Olaparib.
- PathwayBase excision repair, PARP & alkylation damage
Shares Niraparib, Talazoparib, DNA damage response & homologous recombination, PARP inhibitors.
- PersonJohann de Bono
Shares Androgen deprivation & AR pathway inhibitors, PARP inhibitors, Olaparib, Prostate cancer.